Anemia, blood transfusion, and erythropoietin in the critically ill

Clinical Pulmonary Medicine

Volumn 10, Issue 4, 2003, Pages 219-225

  Corwin, Howard L ^a   Hampers, Marcus D ^a   Surgenor, Stephen D ^a  

^a NONE

Author keywords

Blood transfusion; Erythropoietin; Transfusion practice; Transfusion risks

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW; CHRONIC DISEASE; CRITICAL ILLNESS; DISEASE ASSOCIATION; ELECTIVE SURGERY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEMATOCRIT; HOSPITAL ADMISSION; HUMAN; IMMUNE SYSTEM; INFECTION RISK; INTENSIVE CARE; IRON METABOLISM; LABORATORY TEST; MULTIPLE ORGAN FAILURE; PERIOPERATIVE PERIOD; REVIEW; RISK FACTOR; SURGICAL RISK; TREATMENT PLANNING;

EID: 0038167384     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000080905.11193.6e     Document Type: Review

References (89)

1. Spence RK, Cernaiau AC, Carson J, Del Rossi AJ. Transfusion and surgery. Curr Problems Surg. 1993;30:1101-1192.
2. Littenberg B, Corwin HC, Gettinger A, et al. A practice guideline and decision aide for blood transfusion. Immunohematology. 1995;11:88-94.
3. Corwin HC, Parsonnet KC, Gettinger A. RBC transfusion in the ICU: is there a reason? Chest. 1995;108:767-771.
4. Groeger JS, Guntupalli KK, Strosberg M, et al. Descriptive analysis of critical care units in the United States: patient characteristics and intensive care unit utilization. Crit Care Med. 1993;21:279-291.
5. Vincent JL, Baron JF, Gattinoni, L, et al. Anemia and blood transfusion in critical care (ABC) survey: organ function and mortality in transfused patients. JAMA. 2002;288:1199-1503.
6. Corwin HL, Abraham E, Fink MP, et al. Anemia and blood transfusion in the critically ill: current clinical practice in the US-The CRIT Study. Crit Care Med. 2001;29(suppl):A3.
7. Lawrence L. Detailed diagnoses and procedures for patients discharged from short stay hospitals, United States. 1984 Vital and Health Statistics. Series 13: Data from the National Health Survey. No. 86 Department of Health and Human Services Publication No. PHS 86-1747. Hyattsville, MD: National Center for Health Statistics; 1986.
8. Stover EP, LC Seigel, R Parks, et al. Variability in transfusion pratice for coronary artery bypass surgery despite national consensus guidelines. Anesth. 1998;88:327-333.
9. Goodnough LT, Johnston MFM, Toy PTCY. The variability of transfusion practice in coronary artery bypass surgery. JAMA. 1991;265:86-90.
10. Goodnough LT, Soegiarso RW, Birkmeyer JD, et al. Economic impact of inappropriate blood transfusions in coronary artery bypass graft surgery. Am J Med. 1993;94:509-514.
11. Saxena S, Weiner JM, Rabinowitz A, et al. Transfusion practice in medical patients. Arch Intern Med. 1993;153:2575-2580.
12. Welch HG, KR Meehan, LT Goodnough. Prudent stategies for elective red blood cell transfusion. Ann Intern Med. 1992;116:393-402.
13. Carmel R, Shulman IA. Blood transfusion in medically treatable chronic anemia. Arch Pathol Lab Med. 1989;113:995-997.
14. Goodnough LT, ME Brecher, MH Kanter, et al. Transfusion Medicine. New Eng J Med. 1999;340:438-447.
15. Walker RH. Transfusion risks. Am J Clin Pathol. 1987;88:374-378.
16. Blumberg N, Heal JM. Effects of transfusion on immune function. Arch Pathol Lab Med. 1994;118:371-379.
17. Landers DF, Hill GE, Wong KC, et al. Blood transfusion-induced immunomodualation. Anesth Analg. 1996;82:187-204.
18. Mickler TA, Longnecker DE. The immunosuppressive aspects of blood transfusion. J Intensive Care Med. 1992;7:176-188.
19. Vamvakas EC, Craven JH. Allogenic blood transfusion, hospital charges, and length of hospitalization: a study of 487 consecutive patients undergoing colorectal cancer resection. Arch Pathol Lab Med. 1998;122:145-151.
20. Jensen LS, Kissmeyer-Nielsen P, Wolff B, et al. Randomised comparison of leukocyte depleted versus buffy coat poor blood transfusion and complications after colorectal surgery. Lancet. 1996;348:841-845.
21. Blumberg N, Heal JM. Blood transfusion: the silent epidemic. Arch Pathol Lab Med. 1998;122:117-118.
22. American Association of Blood Banks. BPAC recommends universal leukoreduction. AABB News Briefs 1998;20:16.
23. Moore FA, Moore EE, Sauaia A. Blood transfusion: an independent risk factor for post-injury multiple organ failure. Arch Surg. 1997;132:620-625.
24. Manganaro LA, O'Brien JA, Parkar ND, et al. The impact of packed red blood cell transfusions on nosocomial infection rates in the critically ill patient. Crit Care Med. 2000;28(suppl): A103.
25. Mohan A, O'Brien JA, Manganaro L, et al. The association of allogeneic packed red blood cell transfusion with nosocomial bacteremia rate in critically ill patients. Crit Care Med. 2001;29(suppl):A99.
26. Alexiu O, Mircea N, Balaban M, et al. Gastrointestinal hemorrhage from peptic ulcer. An evaluation of bloodless transfusion and early surgery. Anaesthesia. 1975;30:609-615.
27. Dietrich KA, Conrad SA, Hebert CA, et al. Cardiovascular and metabolic response to red blood transfusion in critically ill volume resusitated patients. Crit Care Med. 1990;18:940-944.
28. Lorente JA, Landin L, De Pablo R, et al. Effects of blood transfusion on oxygen transport variables in sepsis. Crit Care Med. 1993;21:1312-1318.
29. Marik PE, Sibbaid WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA. 1993;269:3024-3029.
30. Fitzgerald RD, Martin CM, Dietz GE, et al. Transfusing red blood cells stored in citrate phosphate dextrose adenine-1 for 28 days fails to improve tissue oxygenation in rats. Crit Care Med. 1997;25:726-732.
31. Hebert P, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. New Engl J Med. 1999;340:409-417.
32. Hebert PC, Yetsir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29:227-234.
33. Hebert PC, Blajchman MA, Cook DJ, et al. Do blood transfusions improve outcomes related to mechanical ventilation. Chest. 2001;119:1850-1857.
34. Adam RC, Lundy JS. Anesthesia in cases of poor risk. Some suggestions for decreasing the risk. Surg Gynecol Obstet. 1942;74:1011-1101.
35. Stehling LC, Ellison N, Faust RJ, et al. A survey of transfusion practices among anesthesiologists. Vox Sang. 1987;52:60-62.
36. Hebert PC, Wells G, Martin C, et al. A Canadian survey of transfusion practices in critically ill patients. Crit Care Med. 1998;26:482-487.
37. Levine E, Rosen A, Sehgal L, et al. Physiologic effects of acute anemia: implications for a reduced transfusion trigger. Transfusion. 1990;30:11-14.
38. Geha AS. Coronary and cardiovascular dynamics and oxygen availability during acute normovolemic anemia. Surgery. 1976;80:47-53.
39. Kitchens CS. Are transfusions overrated? Surgical outcome of Jehovah's Witnesses. Am J Med. 1993;94:117-119.
40. Hebert P, Schweitzer I, Calder L, et al. Review of the clinical practice literature on allogeneic red blood cell transfusion. Can Med Assoc J. 1997;156:S9-S26.
41. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998;279:217-221.
42. Carson JL, Spence RK, Poses RM. Severity of anaemia and operative mortality and morbidity. Lancet. 1998;727-729.
43. Spence RK, Carson JA, Poses R, et al. Elective surgery without transfusion: influence of preoperative hemoglobin level and blood loss on mortality. Am J Surg. 1990;159:320-324.
44. Carson JL, Duff A, Poses RM. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996;348:1055-1060.
45. Hardy JF, Martineau R, Couturier A, et al. Influence of haemoglobin concentration after extracorporeal circulation on mortality and morbidity in patients undergoing cardiac surgery. Br J Anaesth. 1998;81:38-45.
46. Nelson AH, Fleisher LA, Rosenbaum SH. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med. 1993;21:860-866.
47. Baxter BT, Minion DJ, McCance CL, et al. Rational approach to postoperative transfusion in high-risk patients. Am J Surg. 1993;166:720-725.
48. Monk TG, Goodnough LT, Brecher M, et al. A prospective randomized comparison of three blood conservation strategies for radical prostatectomy. Anesthesiology. 1999;91:24-33.
49. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. N Engl J Med. 1986;314:1233-1235.
50. Eyster E, Bernene J. Nosocomial anemia. JAMA. 1973;223:73-74.
51. Tarpey J, Lawler PG. Iatrogenic anaemia? A survey of venesection in patients in the intensive therapy unit. Anaesthesia. 1990;45:396-398.
52. Bumum JF. Medical vampires. N Engl J Med. 1986;314:1250-1251.
53. Rodriguez RM, Corwin HL, Pearl RG, et al. Anemia in the critically ill: role of nutritional deficiency and erythropoietin response. J Crit Care. 2001;16:36-41.
54. Van Iperen CE, Gaillard CAJM, Kraaijenhagen RJ, et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unt patients. Crit Care Med. 2000;28:2773-2778.
55. Gabriel A, Kozek S, Chiari A, et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfuction syndrome. J Trauma. 1998;44:361-336.
56. Rogiers P, Zhang H, Leeman M, et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med. 1997;23:159-162.
57. Krafte-Jacobs B, Levetown ML, Bray GL, et al. Erythropoietin response to critical illness. Crit Care Med. 1994;22:821-826.
58. Frede S, Fandrey J, Pagel H, et al. Erythropoieitn gene expression is suppressed after lipopolysaccharide or interluekin-1B injections in rats. Am J Physiol. 1997;272:R1067-R1071.
59. Jelkmann W. Proinflammatory cytikines lowering erythropoieitn production. J Interferon Cytokine Res. 1998;18:555-559.
60. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992;80:1639-1647.
61. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci. 1994;307:353:353-359.
62. Blick M, Sherwin SA, Rosenblum M, et al. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987;47:2986-2989.
63. Levine EA, Gould SA, Rosen AL, et al. Perioperative recombinant human erythropoietin. Surgery. 1989;106:432-438.
64. Levine EA, Rosen AL, Sehgal LR, et al. Treatment of acute postoperative anemia with recombinant human erythropoietin. J Trauma. 1989;29:1134-1139.
65. Goodnough LT, Price TH, Parvin CA, et al. Erythropoietin response to anemia is not altered by surgery of recombinant human erythropoietin. Br J Haematol. 1994;87:695-699.
66. Keating EM. Current options and approaches for blood management in orthopedic surgery. J Bone Joint Surg. 1998:80;750-762.
67. Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet. 1993;341:1227-1232.
68. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopedic operation. J Bone Joint Surg. 1996;78:62-72.
69. De Andrade JR, Jove M, Landon G, et al. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop. 1997;25:533-542.
70. Heiss MM, Tarabichi A, Delanoff C, et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer: a double-blind randomized study. Surgery. 1996;119:523-527.
71. Poulsen KA, Qvist N, Winther K, et al. Haemostatic aspects of recombinant erythropoietin in colorectal surgery. Eur J Surg. 1998;164:211-215.
72. Qvist N, Boesby S, Wolff B, et al. Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: reduced need for blood transfusions in patients undergoing colorectal surgery. World J Surg. 1999;23:30-35.
73. Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(suppl 2):13-19.
74. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alga in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times weekly dosing. J Clin Oncol. 2001;19:2875-2882.
75. Keating EM, Ranawat CS, Cats-Baril W. Assessment of postoperative vigor in patients undergoing elective total joint arthroplasty: a concise patient and caregiver based instrument. Orthop. 1999;22:S119-S128.
76. Sowade O, Ziemer S, Sowade B, et al. The effect of preoperative recombinant erythropoietin therapy on platlets and hemostasis in patients undergoing cardiac surgery. J Lab Clin Med. 1997;129:376-383.
77. Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogneic blood transfusions by treatment with epoetin β (recombinant human erythropoietin) in patients undergoing openheart surgery. Blood. 1997;89:411-418.
78. D'Ambria MN, Gray RJ, Hillman R, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997;64:1686-1693.
79. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl J Med. 1998;339:584-590.
80. NKF-K/DOQI. Clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis. 2001;37:S187-S235.
81. De Andrade JR, Frei D, Guilfoyle M. Integrated analysis of thrombotic/vascular event occurrence in epoetin α treated patients undergoing major, elective orthopedic surgery. Orthopedics. 1999;22:S113-S118.
82. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized double blind placebo controlled trial. Crit Care Med. 1999;27:2346-2350.
83. Consensus Conference. Perioperative red blood cell transfusion. JAMA. 1988;260:2700-2703.
84. Practice strategies for elective blood cell transfusion. Ann Intern Med. 1992;116:403-406.
85. Fang WC, Helm RE, Krieger KH, et al. Impact of minimum hematocrit during cardiopulmonary bypass on mortality in patients undergoing coronary artery surgery. Circulation. 1997;96:194-199.
86. DaFoe GR, Ross CS, Olmstead EM, et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Ann Thorac Surg. 2001;71:769-776.
87. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469-475.
88. Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant. 2002;17(Suppl 5):42-47.
89. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized double blind placebo controlled trial. JAMA. 2002;288:2827-2835.